Boehringer Ingelheim axes biosimilars development outside USBoehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira Share XBoehringer Ingelheim axes biosimilars development outside UShttps://pharmaphorum.com/news/boehringer-ingelheim-axes-biosimilars-development-outside-us/
NICE approves Bayer’s liver cancer drugNICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review Share XNICE approves Bayer’s liver cancer drughttps://pharmaphorum.com/news/nice-approves-bayers-liver-cancer-drug/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
Mundipharma’s Neulasta biosimilar approved in EUA second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU Share XMundipharma’s Neulasta biosimilar approved in EUhttps://pharmaphorum.com/news/mundipharmas-neulasta-biosimilar-approved-in-eu/
New UK drug pricing deal promises faster medicines accessThe UK government has reached a new five-year medicines pricing deal with the pharma industry to replace the Share XNew UK drug pricing deal promises faster medicines accesshttps://pharmaphorum.com/news/new-uk-drug-pricing-deal-promises-faster-medicines-access/
Novartis/Spark’s sight gene therapy approved in EUSpark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there Share XNovartis/Spark’s sight gene therapy approved in EUhttps://pharmaphorum.com/news/novartis-sparks-sight-gene-therapy-approved-in-eu/
Pfizer to hike prices of 41 drugs despite Trump criticismPfizer plans to raise the prices of 41 prescription drugs in January, despite falling foul of President Trump, Share XPfizer to hike prices of 41 drugs despite Trump criticismhttps://pharmaphorum.com/news/pfizer-to-hike-prices-of-41-drugs-despite-trump-criticism/
Pfizer hit by UK Supreme Court ruling on Lyrica patentPfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to Share XPfizer hit by UK Supreme Court ruling on Lyrica patenthttps://pharmaphorum.com/news/pfizer-hit-by-uk-supreme-court-ruling-on-lyrica-patent/
Vertex told to reveal CF drug price, as MPs begin inquiryUK politicians could go public with the price of Vertex’s cystic fibrosis drug Orkambi, if the company does Share XVertex told to reveal CF drug price, as MPs begin inquiryhttps://pharmaphorum.com/news/vertex-told-to-reveal-cf-drug-price-as-mps-begin/
NICE rejects AZ’s Lynparza tablets in ovarian cancer maintenanceAstraZeneca has said it will continue pricing negotiations with the NHS and NICE after the cost-effectiveness body said Share XNICE rejects AZ’s Lynparza tablets in ovarian cancer maintenancehttps://pharmaphorum.com/news/nice-rejects-azs-lynparza-tablets-in-ovarian-cancer-maintenance/
AbbVie sues NHS over hep C drug procurement schemeAmerican pharma firm AbbVie is taking NHS England to court over a procurement process aimed to help England Share XAbbVie sues NHS over hep C drug procurement schemehttps://pharmaphorum.com/news/abbvie-sues-nhs-over-hep-c-drug-procurement-scheme/
Democrats vow to tackle drug prices after midterm victoryDrug companies could come under increased pressure to lower prices in the US, after the opposition Democrat party Share XDemocrats vow to tackle drug prices after midterm victoryhttps://pharmaphorum.com/news/democrats-vow-to-tackle-drug-prices-after-midterm-victory/
Novartis says $4m price is reasonable for SMA gene therapyNovartis says it thinks its one-off gene therapy for spinal muscular atrophy (SMA) could deliver value for money Share XNovartis says $4m price is reasonable for SMA gene therapyhttps://pharmaphorum.com/news/novartis-says-4m-price-is-reasonable-for-sma-gene-therapy/
Sandoz axes filing of US Rituxan biosimilarSandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved Share XSandoz axes filing of US Rituxan biosimilarhttps://pharmaphorum.com/news/sandoz-axes-filing-of-us-rituxan-biosimilar/
Vertex wins European approval for new cystic fibrosis combinationEuropean regulators have approved Vertex’s new cystic fibrosis (CF) combination treatment Symkevi. The European Commission’s greenlight for Symkevi Share XVertex wins European approval for new cystic fibrosis combinationhttps://pharmaphorum.com/news/vertex-european-approval-cystic-fibrosis/
FDA approves biosimilar of blockbuster HumiraA Humira biosimilar, produced by drug maker Sandoz, has been given the green light from the US Food Share XFDA approves biosimilar of blockbuster Humirahttps://pharmaphorum.com/news/fda-approves-biosimilar-blockbuster-humira/
UK opens doors to cannabis-based therapies via NHSMedical cannabis is available to certain patients across the UK for the first time from today. The groundbreaking Share XUK opens doors to cannabis-based therapies via NHShttps://pharmaphorum.com/news/medicinal-cannabis-legal-nhs/
Roche claims US approval for novel flu treatmentThe US FDA has given a green light to a new influenza treatment from Shionogi and Roche that Share XRoche claims US approval for novel flu treatmenthttps://pharmaphorum.com/news/roche-claims-us-approval-novel-flu-treatment/
